A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making

In clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on...

Full description

Bibliographic Details
Main Authors: Xiaotian Chen, Alan Hartford, Jun Zhao
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Contemporary Clinical Trials Communications
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865420300466
id doaj-98cfd928fdc8427399861c140ef41492
record_format Article
spelling doaj-98cfd928fdc8427399861c140ef414922020-11-25T02:44:53ZengElsevierContemporary Clinical Trials Communications2451-86542020-06-0118100562A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-makingXiaotian Chen0Alan Hartford1Jun Zhao2Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, United States; Corresponding author.Statistical and Quantitative Sciences, Takeda Pharmaceuticals Inc, Cambridge, MA, United StatesData Science, Astellas Pharma Global Development, Northbrook, IL, United StatesIn clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on a surrogate endpoint available at an earlier interim may be preferred for selecting which dose to continue. We propose a Bayesian model-based approach where historical data can be leveraged to incorporate a correlation model for investigating the design's operating characteristics. Simulation studies were conducted and the method can be readily applied for power and sample size calculations.http://www.sciencedirect.com/science/article/pii/S2451865420300466Adaptive designBayesian modelCombination testSurrogate markerSurvival analysisHistorical data
collection DOAJ
language English
format Article
sources DOAJ
author Xiaotian Chen
Alan Hartford
Jun Zhao
spellingShingle Xiaotian Chen
Alan Hartford
Jun Zhao
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
Contemporary Clinical Trials Communications
Adaptive design
Bayesian model
Combination test
Surrogate marker
Survival analysis
Historical data
author_facet Xiaotian Chen
Alan Hartford
Jun Zhao
author_sort Xiaotian Chen
title A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
title_short A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
title_full A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
title_fullStr A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
title_full_unstemmed A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
title_sort model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
publisher Elsevier
series Contemporary Clinical Trials Communications
issn 2451-8654
publishDate 2020-06-01
description In clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on a surrogate endpoint available at an earlier interim may be preferred for selecting which dose to continue. We propose a Bayesian model-based approach where historical data can be leveraged to incorporate a correlation model for investigating the design's operating characteristics. Simulation studies were conducted and the method can be readily applied for power and sample size calculations.
topic Adaptive design
Bayesian model
Combination test
Surrogate marker
Survival analysis
Historical data
url http://www.sciencedirect.com/science/article/pii/S2451865420300466
work_keys_str_mv AT xiaotianchen amodelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking
AT alanhartford amodelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking
AT junzhao amodelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking
AT xiaotianchen modelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking
AT alanhartford modelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking
AT junzhao modelbasedapproachforsimulatingadaptiveclinicalstudieswithsurrogateendpointsusedforinterimdecisionmaking
_version_ 1724765407384961024